H11-hKLK2/hKLK3 Mouse
Product Name
H11-hKLK2/hKLK3 Mouse
Product ID
C002068
Strain Name
C57BL/6NCya-Igs2em1(hKLK2/hKLK3)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “H11-hKLK2/hKLK3 Mouse (Catalog C002068) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
KLK3 & KLK2
Gene Alias
APS, PSA, hK3, KLK2A1, hK2, hGK-1, KLK2A2
NCBI ID
Chromosome
Chr 19 (Human), Chr 19 (Human)
MGI ID
--
Datasheet
Strain Description
Kallikrein-related peptidase 2 (KLK2, human kallikrein 2, hK2) and kallikrein-related peptidase 3 (KLK3, prostate-specific antigen, PSA) are members of the kallikrein-related peptidase family. Both are androgen-regulated serine proteases that are highly expressed in prostate epithelial cells. KLK3 encodes prostate-specific antigen (PSA), which is an important biomarker for prostate cancer (PCa) diagnosis and disease monitoring. KLK2 is involved in prostate cancer cell proliferation, invasion, and tumor microenvironment regulation. Altered expression or regulation of KLK2/KLK3 is associated with prostate cancer progression and therapeutic responses [1-3]. The mouse genome lacks direct orthologs of KLK2 and KLK3.
The H11-hKLK2/hKLK3 humanized mouse model was generated by inserting the Human KLK3 promoter-Kozak-Human KLK3 CDS-WPRE-BGH pA-2*beta-globin insulator-Human KLK2 promoter-Kozak-Human KLK2 CDS-WPRE-BGH pA cassette into the mouse H11 locus using gene editing technology. This model can be used to investigate the roles of human KLK2/KLK3 in prostate cancer development and tumor immunoregulation. Its applications mainly include the screening, development, and evaluation of KLK2/KLK3-targeted therapeutics and immunotherapy strategies, as well as prostate cancer disease mechanism studies. It can be used to evaluate therapeutic approaches targeting KLK2-related antigens, including CAR-T cell therapy, bispecific antibodies, and KLK3-associated cancer vaccines, for their potential roles in cancer treatment.
Reference
Srinivasan S, Kryza T, Bock N, et al. A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nat Commun. 2024;15(1):9587. Published 2024 Nov 6.
McKay RR, Nazari SS, Elliott A, et al. Molecular Characterization of KLK2 RNA Expression in Prostate Cancer. Clin Cancer Res. 2026;32(11):2293-2304.
Shen F, Smith R, McDevitt T, et al. Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. Clin Cancer Res. 2025;31(21):4543-4556.
Strain Strategy
The Human KLK3 promoter-Kozak-Human KLK3 CDS-WPRE-BGH pA-2*beta-globin insulator-Human KLK2 promoter-Kozak-Human KLK2 CDS-WPRE-BGH pA cassette was insert to the mouse H11 locus.
Figure 1. Gene editing strategy of H11-hKLK2/hKLK3 mice.
Application Area
Screening, development, and evaluation of KLK2/KLK3-targeted drugs and immunotherapy strategies;
Development and evaluation of immunotherapy strategies for prostate cancer (PCa).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
